Maxime Verhoeven

94 Chapter 5 Supplementary Table S2 Comparative treatment effects of different TCZ-regimens on preventing radiographic progression in early RA, stratified analyses. total SvdH Erosions JSN total SvdH Erosions JSN Relative Risk (95%CI) Relative Risk (95%CI) Relative Risk (95%CI) Relative Risk (95%CI) Relative Risk (95%CI) Relative Risk (95%CI) TCZ vs. TCZ+MTX 1 Effect in patients with low baseline damage # Effect in patients with high baseline damage $ Treatment (TCZ) 0.91 (0.81 to 1.02) 0.95 (0.86 to 1.05) 0.97 (0.87 to 1.07) 1.02 (0.87 to 1.18) 1.03 (0.91 to 1.17) 0.96 (0.87 to 1.06) Effect in patients with low baseline disease activity # Effect in patients with high baseline disease activity $ Treatment (TCZ) 1.04 (0.93 to 1.17) 1.02 (0.93 to 1.11) 0.98 (0.89 to 1.08) 0.92 (0.83 to 1.03) 0.97 (0.88 to 1.07) 0.96 (0.88 to 1.05) Number of patients in low level baseline joint damage subgroup; 160 in TCZ vs. 166 in TCZ+MTX, number of patients in high level baseline joint damage subgroup; 129 in TCZ vs. 132 in TCZ+MTX. Number of patients in low level baseline DAS28 subgroup; 149 in TCZ vs. 145 in TCZ+MTX, number of patients in high level baseline DAS28 subgroup; 146 in TCZ vs. 153 in TCZ+MTX. TCZ= tocilizumab, MTX= methotrexate, DAS28= disease activity score assessing 28 joints, SvdH= Sharp van der Heijde, JSN= joint space narrowing. $ Subgroup baseline SvdH score/DAS28 > median; # Subgroup baseline SvdH score/DAS28 ≤ median 1 = cut-off SvdH score of 1, baseline DAS28 of 6.3